Adheron Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Adheron Therapeutics, Inc. - overview
Established
2006
Location
Berkeley, CA, US
Primary Industry
Pharmaceuticals
About
Adheron Therapeutics, Inc. is dedicated to developing innovative therapies targeting autoimmune, inflammatory, and fibrotic diseases, focusing on Cadherin-11 (Cad-11) inhibitors to improve patient health outcomes. Adheron Therapeutics develops therapies for autoimmune and inflammatory diseases, founded in 2006 in Berkeley, US. The firm was acquired by Roche Holding AG in October 2015 for USD 105 mn.
The company has not undergone significant operational pivots or changes since its inception. Adheron Therapeutics focuses on developing innovative therapies aimed at addressing autoimmune, inflammatory, and fibrotic diseases, with a core emphasis on Cadherin-11 (Cad-11) inhibitors. These products are designed to disrupt pathological fibrosis and inflammatory pathways that lead to chronic conditions such as rheumatoid arthritis and various fibrotic disorders in organs like the lungs and skin. Adheron aims to provide relief and improve the quality of life for patients suffering from debilitating health issues, leveraging the pioneering discoveries of Dr.
Michael Brenner. The company's research initiatives include clinical trials and pipeline programs primarily targeting North American and European markets. Adheron Therapeutics operates on a business model that encompasses direct partnerships with pharmaceutical companies and academic institutions, facilitating collaborative research and development. Revenue generation is driven primarily through licensing agreements and partnerships that support the commercialization of their Cad-11 inhibitor therapies.
Transactions may involve formal agreements for research collaborations, supply agreements for clinical trial materials, and potential profit-sharing arrangements for successful product launches. The company focuses on advancing therapeutic options in the life sciences sector. Adheron Therapeutics plans to utilize its recent acquisition by Roche Holding AG in October 2015 for USD 105 mn to enhance its research and development on new Cad-11 inhibitor therapies. The company is expected to expand its clinical trials and initiatives in North America and Europe, aiming to introduce new products addressing fibrotic and autoimmune diseases by 2025.
These efforts will be supported by strategic partnerships and collaborative agreements established during its operational growth.
Current Investors
HealthCare Ventures, SR One, MedImmune Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
adherontherapeutics.com
Total Amount Raised
Subscriber access only
Adheron Therapeutics, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman Of The Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.